InventisBio (SHA:688382) completed the enrollment of subjects for the phase 3 trial of its D-2570 drug for moderate-to-severe plaque psoriasis, according to a Friday filing with the Shanghai bourse.
The drug could also be used to treat other autoimmune diseases, the filing said.
D-2570 also received phase 2 drug trial approval for psoriasis in the U.S., the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments